Posted by Michael Wonder on 14 Aug 2019
Syapse announces research collaboration with the FDA focused on the regulatory use of real-world evidence
14 August 2019 - Collaboration will advance the derivation of real-world oncology endpoints and provide insights into the use of real-world evidence to support clinical and regulatory decision-making.
Syapse and the U.S. FDA Oncology Center of Excellence (OCE) have signed a multi-year research collaboration agreement focused on the use of real-world evidence to support regulatory decision-making.
Syapse and the OCE will work with stakeholders across the FDA to address key regulatory questions about testing and treatment patterns, dosing and safety, and outcomes in oncology, with a focus on precision medicine.
